Celularity Inc. received a Nasdaq compliance notification due to delayed financial reporting, with a plan to address it.
Quiver AI Summary
Celularity Inc. announced that it received a notification from Nasdaq on May 27, 2026, indicating it is not in compliance with Listing Rule 5250(c)(1) due to a delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026. While this notification does not immediately affect the trading of Celularity's stock, which continues to trade under the symbol "CELU," the company has 60 days, until July 28, 2026, to submit a plan to regain compliance. If accepted, Nasdaq may extend the compliance deadline by up to 180 days. Celularity is currently working to submit its Form 10-Q promptly and aims to meet its SEC reporting obligations.
Potential Positives
- The notification letter from Nasdaq has no immediate impact on the listing or trading of the Company’s common stock, allowing it to continue trading under the symbol “CELU.”
- Celularity has been given a 60-day period to submit a plan to regain compliance, providing it an opportunity to rectify the situation.
- If Nasdaq accepts the Company’s compliance plan, it may grant an extension of up to 180 days to regain compliance, allowing for additional time to meet regulatory requirements.
- The Company is actively working to complete and file its Form 10-Q, demonstrating a proactive approach to return to compliance with SEC reporting obligations.
Potential Negatives
- The Company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1) due to delayed filing of its Quarterly Report, which raises concerns about its operational and financial reporting capabilities.
- The notification from Nasdaq could indicate potential future difficulties in meeting regulatory requirements, negatively impacting investor confidence.
- The need to submit a plan to regain compliance within 60 days may distract the Company from its core business operations and strategic initiatives.
FAQ
What triggered Celularity's notification from Nasdaq?
Celularity received a notification for delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026.
Is Celularity currently in compliance with Nasdaq rules?
No, Celularity is currently not in compliance with Nasdaq Listing Rule 5250(c)(1) due to delayed filings.
How will this affect Celularity's stock trading?
The notification does not have an immediate impact on the trading of Celularity's common stock, which continues on Nasdaq.
What steps is Celularity taking to regain compliance?
The Company is actively working to complete and file its Form 10-Q as soon as possible and expects to regain compliance.
What is the deadline for Celularity to submit its compliance plan?
Celularity has until July 28, 2026, to submit a plan to Nasdaq to regain compliance.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CELU Hedge Fund Activity
We have seen 12 institutional investors add shares of $CELU stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- YORKVILLE ADVISORS GLOBAL, LP removed 100,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $111,000
- CITADEL ADVISORS LLC removed 77,657 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $103,283
- RENAISSANCE TECHNOLOGIES LLC removed 42,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $46,620
- JANE STREET GROUP, LLC removed 41,312 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $54,944
- GEODE CAPITAL MANAGEMENT, LLC added 30,886 shares (+19.3%) to their portfolio in Q1 2026, for an estimated $41,078
- CENTERSTAR ASSET MANAGEMENT, LLC added 17,850 shares (+inf%) to their portfolio in Q1 2026, for an estimated $23,740
- IPG INVESTMENT ADVISORS LLC added 17,169 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,057
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company’s delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission.
The Nasdaq notification letter has no immediate impact on the listing or trading of the Company’s common stock, which continues to trade on the Nasdaq Capital Market under the symbol “CELU.” Nasdaq has provided the Company with a 60-day period, or until July 28, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the prescribed due date of the Form 10-Q, or until November 16, 2026, to regain compliance.
The Company is actively working to complete and file its Form 10-Q as soon as practicable and expects to return to full compliance with its SEC reporting obligations and Nasdaq Listing Rule 5250(c)(1).
About Celularity
Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta’s unique biology, immunologic properties, and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.
For more information, visit www.celularity.com .
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s compliance with Nasdaq listing requirements, the Company’s ability to file its Form 10-Q, the timing of any such filing, the Company’s ability to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1), Nasdaq’s acceptance of any such plan, the Company’s ability to regain compliance within any applicable cure period and the Company’s SEC reporting obligations. These forward-looking statements are based on current beliefs, expectations, and assumptions and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties are described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.
Carlos Ramirez
Senior Vice President, Celularity Inc.
[email protected]
